SCHEMBL2597089

SCHEMBL2597089

CCc1cnc(N2CCC(N)CC2)nc1

nearest known ligand 0.42

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
OGA O60502 1/20 0.42
GPR119 Q8TDV5 12/20 0.41
PDE8B O95263 1/20 0.41
KDM4E B2RXH2 1/20 0.41
NPC1 O15118 1/20 0.41
RAB9A P51151 1/20 0.41
CKS1B P61024 1/20 0.40
SKP1 P63208 1/20 0.40
SKP2 Q13309 1/20 0.40
PTPN11 Q06124 1/20 0.40
HRH4 Q9H3N8 1/20 0.39
KDM1A O60341 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12503204 0.90 HRH4 (0.47) OGAGPR119PDE8BHRH4
SCHEMBL12239174 0.84 TSHR (0.50) OGAGPR119PDE8BKDM4ENPC1
SCHEMBL14247009 0.84 GPR119 (0.46) OGAGPR119PDE8BKDM4ENPC1
SCHEMBL357797 0.83 AOC3 (0.44) OGAGPR119KDM4ENPC1RAB9A
SCHEMBL15189865 0.83 GPR119 (0.44) OGAGPR119PDE8BKDM4ENPC1
SCHEMBL11957018 0.83 GPR119 (0.46) OGAGPR119PDE8BKDM4ENPC1
SCHEMBL20064433 0.82 HRH3 (0.41) OGAGPR119PDE8BKDM4ENPC1
SCHEMBL12474880 0.82 GPR119 (0.46) OGAGPR119PDE8BKDM4ENPC1
SCHEMBL19450729 0.81 OGA (0.47) OGAGPR119PDE8BKDM4ENPC1
SCHEMBL13587921 0.80 GPR119 (0.49) OGAGPR119CKS1BSKP1SKP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2017175068-A1 THIAZOLOPYRIDINE DERIVATIVES AS GPR119 AGONISTS MANKIND PHARMA LTD. (IN) 2017-10-12 WO disclosed
WO-2017175066-A1 HETEROCYCLIC GPR119 AGONIST COMPOUNDS MANKIND PHARMA LTD. (IN) 2017-10-12 WO disclosed
US-8853213-B2 Bicyclic compound for modulating G protein-coupled receptors HANMI PHARM. CO., LTD (KR) 2014-10-07 US disclosed
US-8754226-B2 Piperidinyl-substituted lactams as GPR119 modulators ARRAY BIOPHARMA INC. (US) 2014-06-17 US disclosed
US-8754226-B2 Piperidinyl-substituted lactams as GPR119 modulators ARRAY BIOPHARMA INC. (US) 2014-06-17 US disclosed
US-8754226-B2 Piperidinyl-substituted lactams as GPR119 modulators ARRAY BIOPHARMA INC. (US) 2014-06-17 US disclosed
EP-2661438-A2 NEW BICYCLIC COMPOUND FOR MODULATING G PROTEIN-COUPLED RECEPTORS Hanmi Pharm. Co., Ltd. (KR) 2013-11-13 EP disclosed
US-20130274268-A1 NEW BICYCLIC COMPOUND FOR MODULATING G PROTEIN-COUPLED RECEPTORS HANMI PHARM. CO., LTD (KR) 2013-10-17 US disclosed
CN-103328482-A New bicyclic compound for modulating G protein-coupled receptors HANMI PHARM IND CO LTD 2013-09-25 CN disclosed
US-20130158009-A1 PIPERIDINYL-SUBSTITUTED LACTAMS AS GPR119 MODULATORS ARRAY BIOPHARMA, INC. 2013-06-20 US disclosed
US-20130158009-A1 PIPERIDINYL-SUBSTITUTED LACTAMS AS GPR119 MODULATORS ARRAY BIOPHARMA, INC. 2013-06-20 US disclosed
US-20130158009-A1 PIPERIDINYL-SUBSTITUTED LACTAMS AS GPR119 MODULATORS ARRAY BIOPHARMA, INC. 2013-06-20 US disclosed
CN-103080101-A Piperidinyl-substituted lactams as GPR119 modulators ARRAY BIOPHARMA INC 2013-05-01 CN disclosed
EP-2571864-A1 PIPERIDINYL-SUBSTITUTED LACTAMS AS GPR119 MODULATORS Array Biopharma, Inc. (US) 2013-03-27 EP disclosed
WO-2012093809-A2 NEW BICYCLIC COMPOUND FOR MODULATING G PROTEIN-COUPLED RECEPTORS HANMI PHARM CO., LTD. (KR) 2012-07-12 WO disclosed
WO-2011146335-A1 PIPERIDINYL-SUBSTITUTED LACTAMS AS GPR119 MODULATORS ARRAY BIOPHARMA INC. (US) 2011-11-24 WO disclosed
WO-2011146335-A1 PIPERIDINYL-SUBSTITUTED LACTAMS AS GPR119 MODULATORS ARRAY BIOPHARMA INC. (US) 2011-11-24 WO disclosed
US-20110166088-A1 BENZOTHIAZOLES AND AZA-ANALOGUES THEREOF USE AS ANTIBACTERIAL AGENTS RANBAXY LABORATORIES LIMITED (IN) 2011-07-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130158009-A1 PIPERIDINYL-SUBSTITUTED LACTAMS AS GPR119 MODULATORS GPR119, GPR139, GPR39 OGA 1296/4885GPR119 1/4885PDE8B 2422/4885
US-20110166088-A1 BENZOTHIAZOLES AND AZA-ANALOGUES THEREOF USE AS ANTIBACTERIAL AGENTS TOP2B, TOP1, POLI OGA 1136/4885GPR119 3929/4885PDE8B 1319/4885
US-20130274268-A1 NEW BICYCLIC COMPOUND FOR MODULATING G PROTEIN-COUPLED RECEPTORS GPR119, GPR65, GPR3 OGA 1463/4885GPR119 1/4885PDE8B 1031/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.